Infectious Diseases News and Research RSS Feed - Infectious Diseases News and Research

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

European Commission grants orphan drug designation to SGX301 for treatment of CTCL

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that the European Commission, acting on the positive recommendation from the European Medicines Agency Committee for Orphan Medicinal Products (COMP), has granted orphan drug designation to synthetic hypericin (the active pharmaceutical ingredient in SGX301) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare disease and a class of non-Hodgkin's lymphoma, a type of cancer of the white blood cells that are an integral part of the immune system. [More]
California Initiative to Advance Precision Medicine selects two demonstration projects

California Initiative to Advance Precision Medicine selects two demonstration projects

Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr. [More]
New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

New article proposes creation of $2 billion global vaccine-development fund to prevent infectious diseases

Ebola is a preventable disease, and yet a safe and effective vaccine has not been deployed. As with many vaccines, financial barriers persist: pharmaceutical companies see high costs with limited market potential, and government support is lacking. But there may be a solution to this vaccine crisis with the ability to save at-risk populations, according to a perspective piece written by physicians based at Princeton University, University of Pennsylvania and the Wellcome Trust. [More]
Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern gets $17.5 million NIH grant to invent, develop implantable drug delivery system for HIV prevention

Northwestern Medicine scientists have received a five-year, $17.5 million grant from the National Institutes of Health for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time. [More]
Penn Medicine devises new approach to develop vaccines against lethal diseases

Penn Medicine devises new approach to develop vaccines against lethal diseases

Researchers at the Perelman School of Medicine at the University of Pennsylvania have devised an entirely new approach to vaccines - creating immunity without vaccination. [More]
Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University. [More]

Pitt investigators to lead $5 million initiative to monitor resistance to HIV prevention drugs in sub-Saharan Africa

Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa. [More]
Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix signs $10M equity purchase agreement with accredited institutional investors

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has entered into a $10 million equity purchase agreement with accredited institutional investors, Kodiak Capital Group, LLC, Kingsbrook Opportunities Master Fund LP and River North Equity, LLC. [More]
Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento to develop and market monoclonal antibodies for North American, European and Japanese market

Sorrento Therapeutics, Inc. announced today that it has entered into an exclusive licensing agreement to develop and commercialize multiple prespecified and undisclosed biosimilar or biobetter antibodies from Mabtech Limited, a holding company for premier antibody development and manufacturing companies in China. [More]
Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

Study shows why candidate vaccine used in HVTN 505 clinical trial not protective against HIV infection

A study by researchers at the National Institute of Allergy and Infectious Diseases and Duke University helps explain why the candidate vaccine used in the HVTN 505 clinical trial was not protective against HIV infection despite robustly inducing anti-HIV antibodies: the vaccine stimulated antibodies that recognized HIV as well as microbes commonly found in the intestinal tract, part of the body's microbiome. [More]
IUPUI researchers receive NIH grant to study effect of depression treatment on cardiovascular disease

IUPUI researchers receive NIH grant to study effect of depression treatment on cardiovascular disease

Indiana University-Purdue University Indianapolis researchers led by Jesse Stewart of the School of Science, have received a $2.6 million grant from the National Institutes of Health to conduct the first randomized controlled trial to determine whether depression treatment can help prevent the development of cardiovascular disease. [More]
Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche submits cobas EGFR v2 test PMA to FDA as companion diagnostic test for AZD9291

Roche today announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration, as a companion diagnostic test for AZD9291, an AstraZeneca investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation. [More]
Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas reports topline results from isavuconazole Phase 3 study in candidemia and other invasive Candida infections

Astellas today announced topline results from the Phase 3 ACTIVE study evaluating the efficacy and safety of intravenous (IV) and oral isavuconazole, commercially known as CRESEMBA (isavuconazonium sulfate), under development for adults with candidemia and other invasive Candida infections. [More]
New white paper provides overview of factors that drive vaccination underutilization in older adults

New white paper provides overview of factors that drive vaccination underutilization in older adults

Today the nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a comprehensive overview of the factors that drive vaccination underutilization in seniors and offers recommendations on how industry, government, and health care experts can improve patient compliance. [More]
Cepheid announces international availability of updated Xpert Carba-R test to identify Superbugs

Cepheid announces international availability of updated Xpert Carba-R test to identify Superbugs

Cepheid today announced the international availability of an update to Xpert Carba-R, with the addition of two newly emerging carbapenemase genes, OXA-181 and OXA-232. The on-demand, molecular test also detects and differentiates among the five most prevalent mechanisms of carbapenem resistance, namely KPC, NDM, VIM, IMP-1 and OXA-48. [More]
Commission on Global Health Risk Framework for the Future holds first public meeting

Commission on Global Health Risk Framework for the Future holds first public meeting

Over the past 15 years, outbreaks of Ebola, Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and H1N1 have demonstrated the lack of an adequate local and global health system infrastructure to prevent or mitigate the systemic burdens that result from infectious disease incidents of international significance. [More]
New WFSJ initiative to help journalists report on staggering toll of HCV

New WFSJ initiative to help journalists report on staggering toll of HCV

The World Federation of Science Journalists is launching a new initiative to help journalists report on the staggering toll of Hepatitis C (HCV) as well as the scientific and political barriers to treating the disease. [More]
Two-step regimen of experimental MERS vaccines show promise in mice

Two-step regimen of experimental MERS vaccines show promise in mice

A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines. Vaccinated mice produced broadly neutralizing antibodies against multiple strains of the MERS coronavirus (MERS-CoV), while vaccinated macaques were protected from severe lung damage when later exposed to MERS-CoV. [More]
Study elucidates on global prevalence of chronic hepatitis B infections

Study elucidates on global prevalence of chronic hepatitis B infections

Hepatitis B infections are among the most common infectious diseases worldwide. The disease can become chronic, and is one of the most important causes of severe diseases such as liver cancer. In the scope of an international study funded by the World Health Organization, scientists from the Helmholtz Centre for Infection Research in Braunschweig determined how often the chronic infection occurs in different countries and how many people of the general population are affected. They noted strong differences between different countries. [More]
Point-of-care diagnostics for Ebola

Point-of-care diagnostics for Ebola

In a recent DECODED research profile, Integrated DNA Technologies (IDT), details how IDT scientists Kristin Beltz and Dr Scott Rose are collaborating with Dr Brian Taylor’s research team at Battelle (Aberdeen, MD, USA) to design and validate a RT-qPCR assay that can detect the Ebola virus in the field. [More]
Advertisement
Advertisement